Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus SECREFLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus SECREFLO.
AZMACORT vs SECREFLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
SecReFlo is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by inhibiting presynaptic serotonin reuptake.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
One inhalation (200 mcg albuterol sulfate/80 mcg ipratropium bromide) orally 4 times daily via metered-dose inhaler. May increase to 2 inhalations 4 times daily if needed.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Terminal elimination half-life is 2.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 4.5 hours; in severe impairment (<30 mL/min), half-life is 8 hours, requiring dosage adjustment.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Renal: 75% as unchanged drug; fecal: 20%; biliary: 5%. Total clearance is 0.8 L/h/kg, with renal clearance accounting for 0.6 L/h/kg, indicating active tubular secretion.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-acting Beta Agonist